These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 21273492)

  • 1. The possible protective role of glucagon-like peptide 1 on endothelium during the meal and evidence for an "endothelial resistance" to glucagon-like peptide 1 in diabetes.
    Ceriello A; Esposito K; Testa R; Bonfigli AR; Marra M; Giugliano D
    Diabetes Care; 2011 Mar; 34(3):697-702. PubMed ID: 21273492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vitamin C further improves the protective effect of glucagon-like peptide-1 on acute hypoglycemia-induced oxidative stress, inflammation, and endothelial dysfunction in type 1 diabetes.
    Ceriello A; Novials A; Ortega E; Canivell S; La Sala L; Pujadas G; Bucciarelli L; Rondinelli M; Genovese S
    Diabetes Care; 2013 Dec; 36(12):4104-8. PubMed ID: 24130351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The protective effect of the Mediterranean diet on endothelial resistance to GLP-1 in type 2 diabetes: a preliminary report.
    Ceriello A; Esposito K; La Sala L; Pujadas G; De Nigris V; Testa R; Bucciarelli L; Rondinelli M; Genovese S
    Cardiovasc Diabetol; 2014 Nov; 13():140. PubMed ID: 25407792
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vitamin C further improves the protective effect of GLP-1 on the ischemia-reperfusion-like effect induced by hyperglycemia post-hypoglycemia in type 1 diabetes.
    Ceriello A; Novials A; Ortega E; Canivell S; Pujadas G; La Sala L; Bucciarelli L; Rondinelli M; Genovese S
    Cardiovasc Diabetol; 2013 Jun; 12():97. PubMed ID: 23806096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous GLP-1 and insulin administration acutely enhances their vasodilatory, antiinflammatory, and antioxidant action in type 2 diabetes.
    Ceriello A; Novials A; Canivell S; La Sala L; Pujadas G; Esposito K; Testa R; Bucciarelli L; Rondinelli M; Genovese S
    Diabetes Care; 2014 Jul; 37(7):1938-43. PubMed ID: 24667461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.
    Vilsbøll T; Krarup T; Sonne J; Madsbad S; Vølund A; Juul AG; Holst JJ
    J Clin Endocrinol Metab; 2003 Jun; 88(6):2706-13. PubMed ID: 12788877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.
    Nyström T; Gutniak MK; Zhang Q; Zhang F; Holst JJ; Ahrén B; Sjöholm A
    Am J Physiol Endocrinol Metab; 2004 Dec; 287(6):E1209-15. PubMed ID: 15353407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics.
    Lee A; Patrick P; Wishart J; Horowitz M; Morley JE
    Diabetes Obes Metab; 2002 Sep; 4(5):329-35. PubMed ID: 12190996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance.
    Vollmer K; Holst JJ; Baller B; Ellrichmann M; Nauck MA; Schmidt WE; Meier JJ
    Diabetes; 2008 Mar; 57(3):678-87. PubMed ID: 18057091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucagon-like peptide 1 reduces endothelial dysfunction, inflammation, and oxidative stress induced by both hyperglycemia and hypoglycemia in type 1 diabetes.
    Ceriello A; Novials A; Ortega E; Canivell S; La Sala L; Pujadas G; Esposito K; Giugliano D; Genovese S
    Diabetes Care; 2013 Aug; 36(8):2346-50. PubMed ID: 23564922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of beta-cell secretory capacity using glucagon-like peptide 1.
    Vilsbøll T; Toft-Nielsen MB; Krarup T; Madsbad S; Dinesen B; Holst JJ
    Diabetes Care; 2000 Jun; 23(6):807-12. PubMed ID: 10841001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coffee polyphenol consumption improves postprandial hyperglycemia associated with impaired vascular endothelial function in healthy male adults.
    Jokura H; Watanabe I; Umeda M; Hase T; Shimotoyodome A
    Nutr Res; 2015 Oct; 35(10):873-881. PubMed ID: 26337017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Orlistat augments postprandial increases in glucagon-like peptide 1 in obese type 2 diabetic patients.
    Damci T; Yalin S; Balci H; Osar Z; Korugan U; Ozyazar M; Ilkova H
    Diabetes Care; 2004 May; 27(5):1077-80. PubMed ID: 15111524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Octreotide suppresses the incretin glucagon-like peptide (7-36) amide in patients with acromegaly or clinically nonfunctioning pituitary tumors and in healthy subjects.
    Plöckinger U; Holst JJ; Messerschmidt D; Hopfenmüller W; Quabbe HJ
    Eur J Endocrinol; 1999 Jun; 140(6):538-44. PubMed ID: 10377503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The simultaneous control of hyperglycemia and GLP-1 infusion normalize endothelial function in type 1 diabetes.
    Ceriello A; De Nigris V; Pujadas G; La Sala L; Bonfigli AR; Testa R; Uccellatore A; Genovese S
    Diabetes Res Clin Pract; 2016 Apr; 114():64-8. PubMed ID: 27103371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of the antidiabetic action of subcutaneous glucagon-like peptide-1(7-36)amide in non-insulin dependent diabetes mellitus.
    Schirra J; Leicht P; Hildebrand P; Beglinger C; Arnold R; Göke B; Katschinski M
    J Endocrinol; 1998 Jan; 156(1):177-86. PubMed ID: 9496247
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans.
    Quddusi S; Vahl TP; Hanson K; Prigeon RL; D'Alessio DA
    Diabetes Care; 2003 Mar; 26(3):791-8. PubMed ID: 12610039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.
    Willms B; Werner J; Holst JJ; Orskov C; Creutzfeldt W; Nauck MA
    J Clin Endocrinol Metab; 1996 Jan; 81(1):327-32. PubMed ID: 8550773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in NIDDM.
    Gutniak MK; Linde B; Holst JJ; Efendić S
    Diabetes Care; 1994 Sep; 17(9):1039-44. PubMed ID: 7988303
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Protein/Lipid Preload Attenuates Glucose-Induced Endothelial Dysfunction in Individuals with Abnormal Glucose Tolerance.
    Tricò D; Nesti L; Frascerra S; Baldi S; Mengozzi A; Natali A
    Nutrients; 2020 Jul; 12(7):. PubMed ID: 32664350
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.